home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.480 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

October 03, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Citigroup To $47? Plus This Analysts Predict $95 For Papa John's ↗

October 03, 2022

Goldman Sachs cut Citigroup Inc. (NYSE: C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading.

Via Benzinga

Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% ↗

October 03, 2022

Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...

Via Benzinga

Health Care Company Rocket Pharmaceuticals Announces Acquisition of Renovacor ↗

September 30, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023.

Via Benzinga

Analyst Ratings for Rocket Pharmaceuticals ↗

July 26, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter:

Via Benzinga

4 Analysts Have This to Say About Rocket Pharmaceuticals ↗

July 06, 2022

Within the last quarter, Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings:

Via Benzinga

Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder ↗

May 19, 2022

Via Benzinga

Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗

October 03, 2022

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.

Via Benzinga

Analyst Ratings for Rocket Pharmaceuticals ↗

September 30, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter:

Via Benzinga

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 30, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

September 27, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, STOR, RCKT, RCOR

September 22, 2022

Via ACCESSWIRE

Why Is Renovacor (RCOR) Stock Up 18% Today? ↗

September 20, 2022

Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal.

Via InvestorPlace

Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases ↗

September 20, 2022

Via Benzinga

RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders

September 20, 2022

From Halper Sadeh LLC

Via Business Wire

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

September 20, 2022

From Rocket Pharmaceuticals, Inc. and Renovacor, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 16, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference

September 06, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

August 11, 2022

On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94.

Via Investor's Business Daily

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know ↗

August 09, 2022

Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up...

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

Rocket Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

August 08, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities

July 27, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Why Jim Cramer Says This Stock Is 'Definitely A Buy' ↗

July 20, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is with Tellurian Inc. (NYSE: TELL).

Via Benzinga

Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies ↗

July 08, 2022

Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022 ↗

July 08, 2022

Via Benzinga

Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference

July 08, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Rocket Pharmaceuticals ↗

May 20, 2022

Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com